The question is whether the pipeline can deliver a catalyst big enough to change the narrative before the next cheque is needed. Solvonis has a Phase 3 asset in severe alcohol use disorder, a US programme approaching an IND filing and a discovery compound …
The key question is whether IXICO's "TechBio" pivot, licensing its AI-driven IXI platform to partners rather than relying solely on contract research work, can convert a strengthening order book into a sustainably profitable business. The next data point will be the FY26 full-year results.
Against that sit two potential game-changers that keep aMarket Valueof roughly £26m attached to aBusinesswith £364k of half-year sales: a long-awaited Chinese regulatory decision for partner BYHEALTH, and a gut-microbiomePatentcollaboration with DSM. Which arrives first, a funding crunch or a commercial breakthrough, is the …
Yet the shares trade at around 31p, below the placing price, valuing the Cambridge-basedBusinessat roughly £16.7m. The question for investors is whether the 2025 recovery in order intake converts into sustained growth, and whether new healthcare and consumer wellness initiatives, including a 45,000-participant study …
That money matters because in March the FY2025 accounts warned that funds would last only until the second quarter of 2026, a going-concern uncertainty the rights issue has since removed. With a placebo-controlled Phase 2b study, BEXERA, due to start in the second half …
Yet 2026 has brought a wholesale reset. A new chief executive arrived in June with a Swiss skincareBrandand a £250,000Loanfacility, the board was rebuilt in July, and cash pay has been cut by at least half. The question for anyone watching INC is whether …
• The interim results for the six months to 30 June 2026 showedRevenueof £1.62m against £1.00m in the first half of 2025.
ConvaTec Group Plc — LSE:CTEC closed 0.18% lower on09 September 2026, with the shares at 221.00p after a decline of 0.40p on the day.
GSK Plc — LSE:GSK closed 0.39% higher on09 September 2026, with the shares at 1,803.50p after a gain of 7.00p on the day.
Haleon Plc — LSE:HLN closed 0.74% lower on09 September 2026, with the shares at 334.80p after a decline of 2.50p on the day.